tbuckley/cabot-search huggingface dataset:
循環器病の診断と治療に関するガイドライン(2002-2003年度合同研究班報告)不整脈薬物治療に関するガイドライン
Authors: 児玉逸雄, 相沢義房, 井上博, 大江透, 小川聡, 奥村謙, 笠貫宏, 加藤貴雄, 神谷香一郎
Journal: Circulation (2004)
2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
Authors: Paul A. Heidenreich, Gregg C. Fonarow, Khadijah Breathett, Corrine Y. Jurgens, Barbara A. Pisani, Bunny J. Pozehl, John A. Spertus, Kenneth G. Taylor, Jennifer T. Thibodeau, Clyde W. Yancy, Boback Ziaeian
Journal: Journal of the American College of Cardiology (2020)
Assessment of Birth Defects and Cancer Risk in Children Conceived via In Vitro Fertilization in the US
Authors: Barbara Luke, Morton B. Brown, Hazel B. Nichols, Maria J. Schymura, Marilyn L. Browne, Sarah C. Fisher, Nina E. Forestieri, Chandrika Rao, Mahsa M. Yazdy, Susan T. Gershman, Mary K. Ethen, Mark A. Canfield, Melanie Williams, Ethan Wantman, Sergio Oehninger, Kevin J. Doody, Michael L. Eisenberg, Valerie L. Baker, Philip J. Lupo
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Children with birth defects have a greater risk of developing cancer, but this association has not yet been evaluated in children conceived with in vitro fertilization (IVF). <h3>Objective</h3> To assess whether the association between birth defects and cancer is greater in children conceived via IVF compared with children conceived naturally. <h3>Design, Setting, and Participants</h3> This cohort study of live births, birth defects, and cancer from Massachusetts, New York, North Carolina, and Texas included 1 000 639 children born to fertile women and 52 776 children conceived via IVF (using autologous oocytes and fresh embryos) during 2004-2016 in Massachusetts and North Carolina, 2004-2015 in New York, and 2004-2013 in Texas. Children were followed up for an average of 5.7 years (6 008 985 total person-years of exposure). Data analysis was conducted from April 1 to August 31, 2020. <h3>Exposures</h3> Conception by IVF for state residents who gave birth to liveborn singletons during the study period. Birth defect diagnoses recorded by statewide registries. <h3>Main Outcomes and Measures</h3> Cancer diagnosis as recorded by state cancer registries. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% CIs for birth defect–cancer associations separately in fertile and IVF groups. <h3>Results</h3> A total of 1 000 639 children (51.3% boys; 69.7% White; and 38.3% born between 2009-2012) were in the fertile group and 52 776 were in the IVF group (51.3% boys; 81.3% White; and 39.6% born between 2009-2012). Compared with children without birth defects, cancer risks were higher among children with a major birth defect in the fertile group (hazard ratio [HR], 3.15; 95% CI, 2.40-4.14) and IVF group (HR, 6.90; 95% CI, 3.73-12.74). The HR of cancer among children with a major nonchromosomal defect was 2.07 (95% CI, 1.47-2.91) among children in the fertile group and 4.04 (95% CI, 1.86-8.77) among children in the IVF group. The HR of cancer among children with a chromosomal defect was 15.45 (95% CI, 10.00-23.86) in the fertile group and 38.91 (95% CI, 15.56-97.33) in the IVF group. <h3>Conclusions and Relevance</h3> This study found that among children with birth defects, those conceived via IVF were at greater risk of developing cancer compared with children conceived naturally.
Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates
Authors: Joaquin Martinez-Lopez, Pau Montesinos, Pilar Martinez Sanchez, Julian Gorrochategui, Jose Luis Rojas, Daniel Primo, Juan-Miguel Bergua, Rosa M M. Ayala, Maria Calbacho, Nieves López-Muñoz, Evelyn Acuña, Jose Antonio Pérez-Simón, Adolfo de la Fuente, Jaime Perez De Oteyza, Rebeca Rodríguez-Veiga, Blanca Boluda, Isabel Cano, Joan Ballesteros
Journal: Blood (2020)
A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma
Authors: Won-Seog Kim, Dok-Hyun Yoon, Hyeon-Seok Eom, Youngil Koh, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Yuqin Song, Haiyan Yang, Mei Wang, Jingrun Li, Xubin Huang, Xueyuan Deng, Kan Chen, Zhenfan Yang, Jun Zhu
Journal: Blood (2020)
Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
Authors: Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Irina Kryachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim A Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Y. Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Facon, Maria-Victoria Mateos, Michele Cavo, Hua Chang, Yosef Landesman, Anita A. Joshi, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Sebastian Grosicki, Paul G. Richardson
Journal: Blood (2020)
FRI0201 Circulating procollagen iii aminopropeptide in systemic sclerosis: relationship to a recently validated disease activity index
Authors: S D’Angelo, A Della Rossa, M Caronni, R Scorza, S Bombardieri, G Valentini
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Systemic sclerosis (SSc) is characterised by excessive deposition of extracellular matrix components in the skin and in involved internal organs. Serum levels of procollagen III aminopropeptide (PIIINP), an index of collagen synthesis, have been reported as a possible marker of disease activity in SSc.<sup>1</sup> <h3>Objectives</h3> To study the relationship between a recently developed index of disease activity (2, 3) and serum concentrations of PIIINP. <h3>Methods</h3> Nineteen SSc patients (17 F, 2 M; age ranging from 24 to 76, median 55.5 years; 13 lcSSc, 6 dcSSc; disease duration ranging from 2 to 34, median 12 years) consecutively admitted to 3 Italian tertiary centres and 19 sex and age-matched healthy controls were investigated, for serum levels of PIIINP, by radioimmunoassay. For each SSc patient a recently validated activity index<sup>2,3</sup> was calculated. <h3>Results</h3> Increased serum concentrations of PIIINP were found in SSc compared with controls (4.59 ± 1.84 vs. 3.05 ± 0.85 micrograms/L; p = 0.002). Age, sex, subset and disease duration did not influence PIIINP serum levels. The activity scores calculated in SSc patients ranged from 0.0 to 7.0, median 2.0. No significant correlations were registered between the PIIINP levels and the calculated activity index (rho = 0.04; p &gt; 0.05). <h3>Conclusion</h3> This study demonstrates that elevated PIIINP serum levels found in SSc, even reflecting fibroblast activation, cannot be used as a surrogate for the measurement of disease activity as evaluated by a recently proposed index. <h3>References</h3> Stevens, <i>et al</i>. Br J Rheumatol. 1992;31:683–89 Valentini, <i>et al</i>. Arthritis Rheum. 2000;43:S9-S392 Valentini, <i>et al</i>. Ann Rheum Dis. 2001, in press
Neoantigens in Patients with <i>De Novo</i> Follicular Lymphoma: Results from the PRIMA Study
Authors: Carsten Henneges, Dexter X Jin, Jeffrey M Venstrom, Sally E Trabucco, Tina G Nielsen, Elicia M. Penuel, Sarah Huet, Gilles Salles, Joseph N Paulson
Journal: Blood (2020)
Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
Authors: Geoffrey L Uy, Michael P. Rettig, Stephanie Christ, Ibrahim Aldoss, Michael T. Byrne, Harry P. Erba, Martha L. Arellano, Matthew C Foster, John E. Godwin, Farhad Ravandi, Peter H. Sayre, Anjali S Advani, Matthew J. Wieduwilt, Ashkan Emadi, Laura C. Michaelis, Patrick J. Stiff, Martin Wermke, Norbert Vey, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Fabio Ciceri, Matteo Giovanni Carrabba, Antonio Curti, Geert Huls, Max S. Topp, Mojca Jongen-Lavrencic, John Muth, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, Jian Zhao, Kathy Tran, Patrick Kaminker, Priyanka Patel, Ouiam Bakkacha, Kenneth Jacobs, Maya Kostova, Jennifer Seiler, Bob Lowenberg, Sergio Rutella, Roland B. Walter, Ezio Bonvini, Jan K Davidson-Moncada, John F. DiPersio
Journal: Blood (2020)
Immediate Pre-Splenectomy Platelet Count Predicts Splenectomy Response in Adult Immune Thrombocytopenia Patients
Authors: O. A. Soboleva, K. I. Ntanisian, E. K. Egorova, A. L. Melikyan, E. G. Gemdzhian, E. I. Pustovaya, O. M. Sorkina, K. R. Sabirov, A. V. Grjimolovskiy, V. G. Savchenko
Journal: Blood (2020)
Abstract 498: Krueppel-like Factor 15 Modulation: A Crispr-based Re-establishment of Homeostatic Transcription in Diseased Mouse and Human Cardiomyocytes
Authors: Eric Schoger, Lavanya M Iyer, Claudia Noack, Cheila Rocha, Mareike Jassyk, Orr Shomroni, Gabriela Salinas, Laura C Zelarayan
Journal: Circulation Research (2020)

An altered transcriptomic profile of cardiomyocytes is a hallmark of cardiac remodelling and heart failure. Re-activation of gene programs necessary for myocardial homeostasis and inhibition of deleterious signalling pathways, such as Wnt/beta-catenin signalling, is therefore therapeutically desirable, however challenging to achieve tissue-specifically. We identified Krueppel-like factor 15 (KLF15) as a cardiac specific inhibitor of Wnt/beta-catenin signalling, lost during heart failure progression in the mouse and human heart. To re-establish endogenous Klf15 expression, we designed a cardiomyocyte specific CRISPR activation mouse model expressing enzymatically inactive Cas9 (dCas9) fused to a transcriptional activator (VPR) under Myh6 promoter control. The dCas9VPR protein is directed by guide RNAs (gRNA), delivered by AAV9, to the promoter region of Klf15 and induces gene expression. We tested activation of Klf15 in the adult myocardium by injecting 15 weeks old Myh6-dCas9VPR mice systemically with AAV9 carrying Klf15 gRNAs and increasing Klf15 transcript levels 8 weeks later up to 1.6 fold compared to controls. Since we found a 0.5 fold change of Klf15 expression upon transverse aortic constriction compared to sham operated mice, we expect the CRISPR activation induced Klf15 activation to be sufficient to re-establish Klf15 expression. As a translational approach and since we demonstrated KLF15-WNT regulation in human cardiomyocytes, we integrated dCas9VPR into human induced pluripotent stem cells (hIPSC) by targeted genome editing at the AAVS1 safe harbour locus and confirmed dCas9VPR expression in hIPSC and in hIPSC-derived cardiomyocytes (hIPSC-CM). We tested KLF15 gRNAs in HEK293 cells and selected the most efficient candidate gRNAs to test Klf15 activation in dCas9VPR-IPSC resulting in an up to 1.7 fold activation compared to controls. For gene activation in dCas9VPR hIPSC-CM, we are currently testing lentivirus constructs to deliver up to 3 gRNAs simultaneously to tailor KLF15 expression. With these prerequisites, we aim to re-activate master regulators of normal cardiomyocyte function in failing cardiomyocytes at physiologically relevant levels, such as KLF15, to test potential therapeutic targets for the prevention of heart failure progression.
Suboptimal Global Transcriptional Response Increases the Harmful Effects of Loss-of-Function Mutations
Authors: Károly Kovács, Zoltán Farkas, Djordje Bajić, Dorottya Kalapis, Andreea Daraba, Karola Almási, Bálint Kintses, Zoltán Bódi, Richard A Notebaart, Juan F Poyatos, Patrick Kemmeren, Frank C P Holstege, Csaba Pál, Balázs Papp
Journal: Molecular Biology and Evolution (2020)

Abstract The fitness impact of loss-of-function mutations is generally assumed to reflect the loss of specific molecular functions associated with the perturbed gene. Here, we propose that rewiring of the transcriptome upon deleterious gene inactivation is frequently nonspecific and mimics stereotypic responses to external environmental change. Consequently, transcriptional response to gene deletion could be suboptimal and incur an extra fitness cost. Analysis of the transcriptomes of ∼1,500 single-gene deletion Saccharomyces cerevisiae strains supported this scenario. First, most transcriptomic changes are not specific to the deleted gene but are rather triggered by perturbations in functionally diverse genes. Second, gene deletions that alter the expression of dosage-sensitive genes are especially harmful. Third, by elevating the expression level of downregulated genes, we could experimentally mitigate the fitness defect of gene deletions. Our work shows that rewiring of genomic expression upon gene inactivation shapes the harmful effects of mutations.
Assisted dying: UK government hints at review as it confirms that travel to clinics abroad is permitted under lockdown
Authors: Ingrid Torjesen
Journal: BMJ (2020)

People who are terminally ill are still allowed to travel to places such as Switzerland to end their life under current lockdown rules in England, the government has confirmed.

The situation was clarified by England’s secretary of state for health and social care, Matt Hancock, in the House of Commons on 5 November. He also acknowledged the need for more evidence and discussion on the impact of the UK’s blanket ban on assisted dying.

Hancock said that the government “would consider collecting data on assisted dying if it was felt that that would improve and contribute to a sensitive debate in parliament on this subject,” including the number of people from the UK who travel to Switzerland for an assisted death.

“We …
Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma
Authors: Adam J Olszewski, Anna D Chorzalska, Max Petersen, Thomas A Ollila, Adam Zayac, Habibe Kurt, Diana O Treaba, John L Reagan, Andrew Hsu, Pamela C Egan, James Butera, William Rafelson, Rabin Niroula, John Vatkevich, Jordan Robison, Ilyas Sahin, Chelsea D Mullins, Patrycja M Dubielecka
Journal: Blood (2020)
Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors
Authors: Hua Qin, An-Dong Zhao, Meng-Li Sun, Kui Ma, Xiao-Bing Fu
Journal: Military Medical Research (2020)

Abstract Background Generation of neurons is essential in cell replacement therapy for neurodegenerative disorders like Parkinson’s disease. Several studies have reported the generation of dopaminergic (DA) neurons from mouse and human fibroblasts by ectopic expression of transcription factors, in which genetic manipulation is associated with potential risks. Methods The small molecules and protein factors were selected based on their function to directly induce human fetal lung IMR-90 fibroblasts into DA neuron-like cells. Microscopical, immunocytochemical, and RT-qPCR analyses were used to characterize the morphology, phenotype, and gene expression features of the induced cells. The whole-cell patch-clamp recordings were exploited to measure the electrophysiological properties. Results Human IMR-90 fibroblasts were rapidly converted into DA neuron-like cells after the chemical induction using small molecules and protein factors, with a yield of approximately 95% positive TUJ1-positive cells. The induced DA neuron-like cells were immunopositive for pan-neuronal markers MAP2, NEUN, and Synapsin 1 and DA markers TH, DDC, DAT, and NURR1. The chemical induction process did not involve a neural progenitor/stem cell intermediate stage. The induced neurons could fire single action potentials, which reflected partially the electrophysiological properties of neurons. Conclusion We developed a chemical cocktail of small molecules and protein factors to convert human fibroblasts into DA neuron-like cells without passing through a neural progenitor/stem cell intermediate stage. The induced DA neuron-like cells from human fibroblasts might provide a cellular source for cell-based therapy of Parkinson’s disease in the future.
The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative
Authors: Joseph F. Ferry, Neil Bailey, Vanessa Dunleavy, Joanna Fesler, Judson Hall, Sonia Glennie, William I Bensinger, Raya Mawad, Krish Patel, Daniel Egan, John M. Pagel, Livia Hegerova
Journal: Blood (2020)
Abstract 318: Eicosapentaenoic Acid Improved Nitric Oxide Bioavailability and Reduced Nitroxidative Stress in Human Endothelial Cells in Contrast to Arachidonic Acid <i>In Vitro</i>
Authors: Preston Mason, Hazem Dawoud, Samuel Sherratt, Peter Libby, Deepak L Bhatt, Tadeusz Malinski
Journal: Circulation Research (2020)

Treatment with prescription, high dose, stable icosapent ethyl (IPE), which is eicosapentaenoic acid (EPA), an omega-3 fatty acid (O3FA), significantly reduced clinical events in high-risk patients with diabetes and other risk factors or cardiovascular disease (REDUCE-IT). Previous studies suggest that the benefits of EPA correlate positively with its levels and ratio to arachidonic acid (AA) in circulation. Unlike EPA, AA is an omega-6 fatty acid (O6FA) that, along with its metabolites, contributes to inflammation and diabetes. One mechanism of benefit of an increased EPA to AA ratio may be improved endothelial cell (EC) function, as evidenced by increased nitric oxide (NO) release and decreased nitroxidative (ONOO – ) stress. In this study, human umbilical vein endothelial cells (HUVECs) were pretreated with EPA or AA at equimolar levels (10 μM) at various time points (4-24 hr) in 5% FBS. Following treatment, the cells were stimulated with calcium ionophore and assayed for the ratio of NO and ONOO – release, an indicator of eNOS coupling, using tandem porphyrinic nanosensors. ECs treated with EPA had significantly greater NO release following stimulation compared with vehicle at all time points, including 17% and 21% at 4 and 24 hr, respectively (p&lt;0.05 and p&lt;0.01) without changes in eNOS expression. By contrast, AA did not significantly improve NO production. ECs treated with EPA also showed a non-significant reduction in ONOO - release by 10% at 4 hr and 14% at 24 hr. EPA, but not AA, increased NO/ONOO - release ratio by 42% (4.03 ± 0.06 vs 2.83 ± 0.05; p &lt;0.01) by 24 hr. Thus, EPA increased NO bioavailability in human ECs, unlike AA, due to improved eNOS coupling and reduced oxidative stress. These findings support a preferential benefit of EPA on endothelial function as compared to AA and supports further investigation.
Robust Discovery of Candidate DNA Methylation Cancer Drivers
Authors: Heng Pan, Loïc Renaud, Ronan Chaligne, Johannes Bloehdorn, Eugen Tausch, Daniel Mertens, Anna-Maria Fink, Kirsten Fischer, Chao Zhang, Doron Betel, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, Michael Hallek, Alexander Meissner, Stephan Stilgenbauer, Catherine J. Wu, Olivier Elemento, Dan A. Landau
Journal: Blood (2020)
Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia
Authors: Alida Dominietto, Stefano Vagge, Susanta Hui, Carmen Di Grazia, Teresa Lamparelli, Stefania Bregante, Anna Maria Raiola, Riccardo Varaldo, Francesca Gualandi, Renzo Corvò, Emanuele Angelucci
Journal: Blood (2020)
Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial
Authors: Marzia Varettoni, Simone Ferrero, Cristina Picone, Milena Gilestro, Noemí Puig, Luigi Marcheselli, Irene Dogliotti, Angela Ferrari, Michele Merli, Giulia Zamprogna, Luca Laurenti, Simona Tomassetti, Emanuele Cencini, Giacomo Loseto, Dario Marino, Monia Marchetti, Francesca Re, Antonello Sica, Jacopo Olivieri, Cristina Jiménez, Silvia Zibellini, Daniela Drandi, Chiara Candido, Martina Ferrante, Nicole Fabbri, Federica Cavallo, Luca Arcaini, Mario Boccadoro, Ramon Garcia-Sanz
Journal: Blood (2020)
Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era
Authors: Edith Tama Robin, Esther Drill, Connie Lee Batlevi, Philip Caron, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, Erel Joffe, Anita Kumar, Matthew J Matasar, Ariela Noy, Colette Owens, Maria Lia Palomba, Ildefonso Rodriguez-Rivera, David J. Straus, Santosha Vardhana, Gottfried R. von Keudell, Andrew D Zelenetz, Craig H. Moskowitz, Alison J. Moskowitz
Journal: Blood (2020)
Sox17 and Coronary Arteriogenesis in Development
Authors: Maoying Han, Bin Zhou
Journal: Circulation Research (2020)

oronary artery disease causes acute myocardial infarction, making it one of the leading causes of mortality and morbidity worldwide.An acute coronary artery occlusion can result in the death of a substantial number of cardiomyocytes, leading to myocardial infarction and heart failure.The revascularization of ischemic myocardium by promoting new artery generation or collateral artery formation represents a promising therapeutic approach for treating coronary artery disease.Learning from naturally developing coronary arteriogenesis may be an important step toward the goal of therapeutic neovascularization in adults.Therefore, a better understanding of developmental coronary arteriogenesis would provide critical information and novel insights that might be deployed for therapeutic neovascularization of ischemic myocardium in the future.However, we still do not fully understand how coronary arteries are generated in development and what molecular mechanisms regulate their formation and specification.
Correction to: EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis
Authors: Renjie Wang, Sai Zhang, Xuyi Chen, Nan Li, Jianwei Li, Ruichao Jia, Yuanqing Pan, Haiqian Liang
Journal: Molecular Cancer (2020)

An amendment to this paper has been published and can be accessed via the original article.
Abstract PO-089: Spatial profiling of the tumour microenvironment using digital spatial profiling
Authors: Arutha Kulasinghe
Journal: Cancer Research (2020)

Abstract Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). To identify patient-responders from non-responders, biomarkers are needed which are predictive of outcome to ICI therapy. Cues in the tumour microenvironment (TME) have been informative in understanding the tumour-immune contexture. Methods: In this study, the NanoString GemoMx™ Digital Spatial Profiling (DSP) technology was used to determine the immune marker and compartment specific measurements in a cohort of HNSCC and NSCLC tumours from patients receiving ICI therapy. Results: Our data revealed that markers involved with immune cell infiltration (CD8 T-cells) were not predictive of outcome to ICI therapy. A number of immune cell types (CD4, CD68, CD45, CD44, CD66b) were found to correlate with progressive disease. Conclusions: Our data shows proof of principle for use of digital spatial profiling for the identification of predictive biomarkers for ICI therapy in HNSCC and NSCLC. Citation Format: Arutha Kulasinghe. Spatial profiling of the tumour microenvironment using digital spatial profiling [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-089.
Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel
Authors: Evangelos Terpos, Borhane Slama, Renato Zambello, Sorina Nicoleta Badelita, Eirini Katodritou, Jo Caers, Thomas Kühr, Florence Suzan, Abeera Mohammad, Sally Wetten, Xavier Leleu
Journal: Blood (2020)